News
Investing.com -- Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock plummeted 51% in pre-market trading after the company announced it would sell its cell therapy assets to US WorldMeds for $55 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback